Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
211 Bupivacaine 0.5 % with Adrenaline 1:200,000 Injection N01BB51975P3001XX B Regional nerve block or epidural block. 10 - 40 ml (0.25 %) or maximum : 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml of 0.5% solution
212 Buprenorphine 10mcg/hr transdermal patch N02AE01110M7001XX A* Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Not suitable for the treatment of acute pain. For elderly patients or patients with comorbidities/difficult to swallow Once weekly transdermal patch/for hospital use only. Patient aged 18 years and over. Initial dose: 5 mcg/hr For elderly: Renal impairment. No special dose adjustments necessary in patients with renal impairment Hepatic impairment Patients with hepatic insufficiency should be carefully monitored during the treatment with buprenorphine patch. Alternate therapy should be considered. Patch should be used with cautions in severe hepatic impairment patient
213 Buprenorphine 5mcg/hr transdermal patch N02AE01110M7003XX A* Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Not suitable for the treatment of acute pain. For elderly patients or patients with comorbidities/difficult to swallow Once weekly transdermal patch/for hospital use only. Patient aged 18 years and over. Initial dose: 5 mcg/hr For elderly: Renal impairment. No special dose adjustments necessary in patients with renal impairment Hepatic impairment Patients with hepatic insufficiency should be carefully monitored during the treatment with buprenorphine patch. Alternate therapy should be considered. Patch should be used with cautions in severe hepatic impairment patient
214 Busulfan 2 mg Tablet L01AB01000T1001XX A i) Chronic myeloid leukaemia (CML) and other myeloproliferative diseases ii) Haemopoietic stem cell transplant (HSCT)- refer to specific protocols i) ADULT: Initial: 2 - 4 mg daily. Maintenance: 0.5 - 2 mg daily. Stop when white blood cell less than 20 x 109/L. CHILD: 60 mcg/kg body weight daily ii) CHILD: Induction 60 mcg/kg body weight daily (maximum 4 mg) if leucocytes more than 20,000/mm3 and platelets more than 100,000/mm3. Maintenance 10 - 30mcg/kg (maximum 2 mg daily)
215 Busulfan 6 mg/ml Injection L01AB01000P3001XX A* For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia. To be prescribed by paediatric oncologist and consultant haematologist trained in transplant only. In selected cases with high risk of liver toxicity and intolerance to oral busulfan. 0.8 mg/kg of ideal body weight or actual body weight, whichever is lower via central venous catheter as a 2-hour infusion on the basis of every 6 hours for 4 days, for a total of 16 doses. For obese or severely obese patients, IV Busulfan should be administered based on adjusted ideal body weight
216 Cabergoline 0.5 mg Tablet G02CB03000T1001XX A* i) Treatment of hyperprolactinaemic disorders ii) Prevention of puerperal lactation and suppression of lactation in HIV infected mothers only i)0.5mg per week given in 1 or 2 (one-helf of one 0.5mg tablet) doses per week ii) HIV mothers only : Prevent lactation 2 tab first day after delivery. Interruption of laction : 0.25mg 12 hourly for 2 days
217 Calamine Cream D04AX00000G1001XX C+ Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions. Apply to the affected area as required, 1-3 times daily
218 Calamine Lotion D04AX00000L8001XX C+ Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions. Apply to the skin as required and allow to dry, 1-3 times daily
219 Calamine with 0.25 - 0.5% Menthol Lotion D04AX00952L6001XX C Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions. Apply to the skin as required and allow to dry, 1 - 3 times daily
220 Calamine with 0.5% Phenol Cream D04AX00952G1001XX C For use as a mild astringent Apply to the affected area as required
221 Calamine with 2 - 6% Precipitated Sulphur Lotion D04AX00952L6002XX C Acne vulgaris Apply to the skin as required and allow to dry, 1 - 3 times daily
222 Calcipotriol 50 mcg/g Cream D05AX02000G1001XX A* Only for the treatment of Psoriasis Vulgaris ADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weekly
223 Calcipotriol 50 mcg/g Ointment D05AX02000G5001XX A* Only for the treatment of Psoriasis Vulgaris ADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weekly
224 Calcipotriol Hydrate 50 mcg/g & Betamethasone Dipropionate 0.5 mg/g Ointment D05AX52952G5001XX A* Resistant plaque psoriasis Apply once daily up to 4 weeks with maximum weekly dose of 100g and maximum treatment area 30% of body surface
225 Calcipotriol monohydrate 50 mcg/g and Betamethasone dipropionate 0.5 mg/g Gel D05AX52952G3001XX A* Topical treatment of scalp and non-scalp plaque psoriasis vulgaris in adults Should be applied to affected areas once daily. The recommended treatment period is 4 weeks for scalp areas and 8 weeks for non-scalp areas. The body surface area treated with calcipotriol containing products should not exceed 30% and maximum dose should not exceed 15g or 100g/ week
226 Calcipotriol monohydrate 50mcg/g & Betamethasone Dipropionate 0.5mg/g Cutaneous Foam D05AX52-946-L62-01-XXX A* Resistant plaque psoriasis Second line topical treatment when unresponsive to topical steroid and coal tar Apply once daily up to 4 weeks with maximum daily dose of 15g and maximum treatment area 30% of body surface
227 Calcitonin (synthetic Salmon) 100 IU Injection H05BA01000P3002XX A* Acute hypercalcaemia 5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Renal impairment: Dosage adjustment needed.
228 Calcitonin (Synthetic Salmon) 50 IU Injection H05BA01000P3001XX A* Acute hypercalcaemia 5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Renal impairment: Dosage adjustment needed.
229 Calcitriol 0.25 mcg Capsule A11CC04000C1001XX A/KK i)Established postmenopausal osteoporosis ii) Renal osteodystrophy in patients on haemodialysis iii)Hypoparathyroidism and rickets iv)Secondary hyperparathyroidism in renal failure "i) 0.25 mcg 2 times daily ii) Initial dose 0.25 mcg. In patients with normal or only slightly reduced serum calcium levels, doses of 0.25 mcg every other day is sufficient iii) 0.25 mcg/day given in the morning iv) ADULT and CHILD 3 years and older : Initially 0.25 mcg/ml. CHILD less than 3 years : 10 to 15 ng/kg/day "
230 Calcitriol 1 mcg/ml Injection A11CC04000P3001XX A* Management of hypocalcaemia and/or secondary hyperparathyroidism in patients undergoing chronic renal dialysis Initially dose, depending on severity, 1 mcg (0.02 mg/kg) to 2 mcg 3 times weekly, approximately every other day
231 Calcitriol 2 mcg/ml Injection A11CC04000P3002XX A* Management of hypocalcaemia and/or secondary hyperparathyroidism in patients undergoing chronic renal dialysis Initially dose, depending on severity, 1 mg (0.02 mg/kg) to 2 mg 3 times weekly, approximately every other day
232 Calcium Carbonate 500 mg Capsule A12AA04121C1001XX B To be used only for: i) Hyperphosphatemia (phosphate binder) in chronic renal failure patients ii) Calcium supplementation a) Hyperphosphatemia: i) Stage 3 to 5 chronic kidney disease, total dose of elemental calcium from all sources (ie, dietary and calcium-based phosphate binder) not to exceed 2,000 mg/day ii) Stage 5 chronic kidney disease, total dose of elemental calcium from calcium-based phosphate binder not to exceed 1,500 mg/day b) Calcium supplementation 1,000-2,500mg elemental calcium per day in divided doses (500mg capsule contains 200mg elemental calcium)
233 Calcium Carbonate 500 mg Tablet A12AA04121T1001XX B To be used only for: a) Hyperphosphatemia (phosphate binding activity) in patients with chronic renal failure b) Calcium supplementation a) Hyperphosphatemia: i) Stage 3 to 5 chronic kidney disease, total dose of†elemental†calcium from all sources (ie, dietary and calcium-based phosphate binder) not to exceed 2,000 mg/day ii) Stage 5 chronic kidney disease, total dose of†elemental†calcium from calcium-based phosphate binder not to exceed 1,500 mg/day b) Calcium supplementation 1,000-2,500mg elemental calcium per day in divided doses (500mg tablet contains 200mg elemental calcium)
234 Calcium Chloride Dihydrate, Sodium Chloride, Magnesium Chloride Hexahydrate, Sodium Acetate Trihydrate,Potassium Chloride, and Malic Acid Solution B05BB01905P6002XX A Replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent. The maximum infusion rate depends on the needs of the patient in fluid replacement and electrolytes, patient?s weight, clinical condition, and biological status. Adults, elderly, adolescents:500ml-3L/24hr. Babies, children: 20ml to 100ml/kg/24 hr.
235 Calcium Disodium Edetate 200 mg Injection V03AB03999P3001XX A Lead Poisoning IM (Lead encephalopathy): 1000 mg/m(2)/day IM in divided equal doses 8 to 12 hours apart, for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated. Do not exceed the recommended daily dosage. IV: 1000 mg/m(2)/day administered IV over 8 to 12 hours for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated.
236 Calcium Gluconate 10% Injection A12AA03000P3001XX B i)Acute hypocalcaemia ii)Hypocalcaemic tetany iii)Cardiac resuscitation i) 1-2 g (2.25-4.5 mmol). CHILD 50 mg/kg ii) ADULT 1g (2.2 mmol) by slow IV injection followed by continuous infusion of 4 g (8.8 mmol) daily iii) IV or intracardiac injection, 10 ml
237 Calcium Lactate 300 mg Tablet A12AA05125T1001XX C For prophylaxis of calcium deficiency and treatment of chronic hypocalcaemia ADULT 1-5 g daily in divided doses
238 Calcium Polystyrene Sulphonate Powder V03AE01-999-F21-01-XXX A Hyperkalemia resulting from acute or chronic renal failure - 15 - 30g daily in 2-3 divided doses. Each dose should be suspended in 30 - 50ml of water and administered orally
239 Calfactant 35mg/ml intratracheal suspension R07AA02000L9104XXX A* For the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (“rescue”) of premature infants who develop RDS. Prophylaxis: Indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Should be administered as soon as possible, preferably within 30 minutes after birth. Treatment: Indicated for infants ≤72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation. 3mL/kg body weight at birth to be administered every 12 hours for total up to 3 doses.
240 Capecitabine 150 mg Tablet L01BC06000T1002XX A* 1) Metastatic breast cancer; 2) Treatment of colorectal cancer in adjuvant and metastatic setting; 3) advanced oesophagogastric cancer in combination with a platinum-based regimen. i) & ii) 1250 mg/m2 twice daily (morning and evening) for 2 weeks, every 21 days. iii) Recommended for a total of 24 weeks (8 cycles of 2 weeks of drug administration and 1 week rest period. Iv) In combination with a platinum on day 1, give capecitabine 1250 mg/m2 twice daily for 14 days. Repeated every 3 weeks for 8 cycles or optimum number of cycles

Halaman-halaman